Trial Profile
A trial to examine the effects of lobeglitazone, on changes in Bone mineral density over 52-weeks of treatment compared to placebo in Korean patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 May 2016 New trial record
- 17 Apr 2016 Results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases